Telesis Bio (TBIO) announced a new license agreement with Regeneron Pharmaceuticals (REGN) to deploy Telesis Bio’s Gibson SOLA platform at its R&D core facilities. The company stated this will help Regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs, aiming to accelerate biologics discovery timelines from weeks to hours. The Gibson SOLA platform is designed to enable fully-enzymatic, overnight, on-site synthesis of high-fidelity DNA and mRNA.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue